Health Care Equipment

Weigao Blood Purification

Weigao Blood Purification released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 904.27 M, actual EPS CNY 0.28

Weigao Blood Purification FY2026 Q1 Earnings Release on April 30 After-Market BJT

Weigao Blood Purification released FY2025 Annual Earnings on March 27 After-Market (BJT), Actual Revenue: CNY 3.769 B (Forecast: CNY 3.677 B), Actual EPS: CNY 1.22 (Forecast: CNY 1.09)

Weigao Blood Purification released FY2025 Q4 earnings on March 27 After-Market BJT, actual revenue CNY 1.033 B, actual EPS CNY 0.3738

Weigao Blood Purification to Release FY2025 Annual Earnings on March 28 After-Market (BJT), Forecast Revenue CNY 3.677 B, EPS CNY 1.09

Weigao Blood Purification to Release FY2025 Q3 Earnings on October 31, 2025 (BJT)

Weigao Blood Purification released FY2025 Q3 earnings on October 16 (BJT), actual revenue CNY 971.37 M, actual EPS CNY 0.2719

Weigao Blood Purification released FY2025 9 Months Earnings on October 16, 2025 (BJT) with actual revenue of CNY 2.736 B and EPS of CNY 0.8536

Vega Bio-Net Lists on Shanghai Stock Exchange and Achieves Domestic Substitution of Hemodialysis Materials

Weigao Blood Purification released FY2024 9 Months Earnings on August 27 (BJT), with actual revenue of CNY 2.645 B and actual EPS of CNY 0.8496

Weigao Blood Purification released FY2025 Semi-Annual earnings on August 27 (BJT), actual revenue CNY 1.765 B, actual EPS CNY 0.58

Weigao Blood Purification released FY2025 Q2 earnings on August 27 (BJT), actual revenue CNY 868.69 M, actual EPS CNY 0.2717

Weigao Blood to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Vega Blood Purification Explains Overseas Layout and Peritoneal Dialysis Business Development Strategy

WEGO Blood Purification Plummets After IPO, Evaporating 5 Billion HKD in Market Cap

Weigao Blood Purification Obtains Blood Recovery Device Patent

Weigao Blood Purification Responds to Investors on AI Dialysis Machine Development

Weigao Blood Purification Obtains a New Patent

Weigao Purification Announces Fund-raising Replacement Plan

Weigao Blood Purification Obtains Patent for Pressure Sensor Protection Monitoring Connection Structure

01066

603014

WEIGAO GROUP announced the sale of 95.9784% equity in WEIGAO PURUI to Weigao Blood Purification, with a final consideration of approximately 8.511 billion RMB. Weigao Blood Purification will issue 272 million shares as consideration shares, priced at 31.29 RMB per share. After the transaction is completed, WEIGAO GROUP's shareholding in Weigao Blood Purification will increase from 23.53% to 52.10%, becoming its flagship platform for medical devices

AASTOCKS

WEIGAO GROUP

WEIGAO GROUP sells Weigao Purui for a final consideration of 8.5 billion RMB in exchange for over 260 million A shares of Weigao Blood Purification

Weigao Blood Purification plans to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. through the issuance of shares, with the stock resuming trading on November 3, 2025. This transaction will integrate technology and product layout, expand into the pharmaceutical packaging materials field, and enhance the technical reserves and sales channels of the biopharmaceutical filter business through synergies

Zhitong

Weigao Blood Purification plans to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. Stock resumes trading

On October 17th, WEIGAO GROUP signed a non-binding letter of intent, planning to acquire its 94.0706% stake in Weigao Blood Purification, which focuses on the research and production of pharmaceutical packaging materials. This move will further expand the company's overall business landscape

WEIGAO GROUP is potentially selling over 94% of Weigao Purui to exchange for Weigao Blood Purification A shares

According to the Zhitong Finance APP, Weigao Blood Purification announced that the company is planning to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. (hereinafter referred to as "Weigao Purui" or "the target company") through the issuance of shares. Upon the company's application, the company's stock will be suspended from trading starting from October 20, 2025 (Monday), and the suspension is expected to last no more than 10 trading days

Weigao Blood Purification plans to acquire 100% equity of Weigao Purui, and trading will be suspended from October 20

22093

Shandong Weigao Blood Purification Products Co., Ltd. announced the implementation of the 2025 semi-annual equity distribution, planning to distribute a cash dividend of RMB 0.15756 per share based on a total share capital of 417,754,066 shares, totaling a cash dividend distribution of RMB 65,821,330.64. The equity registration date is October 23, 2025, and the ex-dividend date and cash dividend payment date is October 24. The announcement specifies the tax deduction situation for different types of shareholders

Shandong Weigao Blood Purification Products Co., Ltd.

Weigao Blood Purification will implement the distribution of equity for the first half of 2025, distributing over 65.82 million yuan in cash

Weigao Blood announced that in the first half of 2025, operating revenue was 1.765 billion yuan, a year-on-year increase of 8.52%. Net profit was 220 million yuan, a year-on-year increase of 10.11%. The company plans to distribute a cash dividend of 1.6 yuan for every 10 shares to all shareholders, totaling a cash dividend of 65.8231 million yuan, accounting for 29.89% of the net profit attributable to shareholders of the listed company in the consolidated financial statements

Weigao Blood: Net profit of 220 million yuan in the first half of 2025, a year-on-year increase of 10.11%

China Renaissance Holdings announced that its subsidiary, China Renaissance New Economy Fund, has successfully listed Shandong Weigao Blood Purification Products Co., Ltd. on the main board of the Shanghai Stock Exchange, with the stock code 603014. Weigao Blood Purification is a leading enterprise in China's blood purification industry, focusing on the research and development of hemodialysis and peritoneal dialysis. The China Renaissance New Economy Fund led the pre-IPO financing for Weigao Blood Purification in 2022, with a total investment amount of 450 million RMB, demonstrating recognition and confidence in its industry position

CR HOLDINGS

Hua Xing Capital Holdings: Weigao Blood successfully listed on the main board of the Shanghai Stock Exchange

According to the Zhitong Finance APP, Weigao Blood announced that the company's stock will be listed on the main board of the Shanghai Stock Exchange on May 19, 2025

Weigao Blood stock will be listed on the main board of the Shanghai Stock Exchange on May 19

According to the Zhitong Finance APP, Weigao Blood announced that after the activation of the reallocation mechanism, the final issuance quantity for offline subscriptions was 12.512832 million shares, accounting for 31.78% of the total issuance quantity after deducting the final strategic placement portion. The final issuance quantity for online subscriptions was 26.854500 million shares, accounting for 68.22% of the total issuance quantity after deducting the final strategic placement portion. After the activation of the reallocation mechanism, the final winning rate for online subscriptions was 0.03215719%

After the reallocation, the final online issuance winning rate of Weigao Blood is 0.032%

Weigao Blood started its subscription on May 8, with an issue price of 26.5 yuan per share, a subscription limit of 11,000 shares, and a price-to-earnings ratio of 24.82 times. The company focuses on the fields of hemodialysis and peritoneal dialysis, holding a market share of 32.5% and 31.8% respectively in the domestic hemodialysis machine and tubing markets in 2023, ranking first in both. The funds raised will be used for the company's development projects

Fresenius Medical Care

A-share subscription | Weigao Blood opens subscription, focusing on two major tracks: hemodialysis and peritoneal dialysis

Weigao Blood Purification(603014.SH)